Estrogen and alendronate therapies may prevent the influence of estrogen deficiency on the tooth-supporting alveolar bone: A histometric study in rats

Journal of Periodontal Research

Volumn 41, Issue 6, 2006, Pages 541-546

  Duarte, P M ^a,c   Goncalves P ^b   Casati, M Z ^b   De Toledo, S ^b   Sallum, E A ^b   Nociti Jr , F H ^b  

^a GUARULHOS UNIVERSITY   (Brazil)

^b UNIVERSITY OF CAMPINAS   (Brazil)

^c NONE   (Brazil)

Author keywords

Alveolar bone; Bisphosphonate; Calcitonin; Osteoporosis

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE; BONE DENSITY CONSERVATION AGENT; ESTROGEN;

ANIMAL; ARTICLE; BLOOD; BONE DENSITY; DRUG EFFECT; FEMALE; JAW; OSTEOPOROSIS; PHYSIOLOGY; RAT; WISTAR RAT;

ALENDRONATE; ALKALINE PHOSPHATASE; ALVEOLAR PROCESS; ANIMALS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; ESTROGENS; FEMALE; OSTEOPOROSIS; RATS; RATS, WISTAR;

EID: 33750458959     PISSN: 00223484     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0765.2006.00903.x     Document Type: Article

References (37)

1. Harrison JE. Osteoporosis. In: Tam CS, Heersche JNM, Murray TM, eds. Metabolic Bone Diseases: Cellular and Tissue Mechanisms. Boca Raton: CRC Press, 1989: 240-267.
2. Heaney RP, Recker RR, Saville PD. Menopausal changes in bone remodeling. J Lab Clin Med 1978;92:964-970.
3. Kribbs PJ. Comparison of mandibular bone in normal and osteoporotic women. J Prosthet Dent 1990;63:218-222.
4. Chesnut CH, 3rd. The relationship between skeletal and oral bone mineral density: an overview. Ann Periodontol 2001;6:193-196.
5. Bodic F, Hamel L, Lerouxel E, Basle MF, Chappard D. Bone loss and teeth. Joint Bone Spine 2005;72:215-221.
6. Eriksen EF, Colvard DS, Berg NJ et al. Evidence of estrogen receptors in normal human osteoblast-like cells. Science 1988;241:84-86.
7. Lindberg MK, Erlandsson M, Alatalo SL et al. Estrogen receptor alpha, but not estrogen receptor beta, is involved in the regulation of the OPG/RANKL (osteoprotegerin/ receptor activator of NF-kappa B ligand) ratio and serum interleukin-6 in male mice. J Endocrinol 2001;171:425-433.
8. Pacifici R. Is there a causal role for IL-1 in postmenopausal bone loss? Calcif Tissue Int 1992;50:295-299.
9. Girasole G, Passeri G, Pedrazzoni M, Giuliani N, Passeri M. Interleukin-6: a pathogenetic role in the postmenopausal osteoporosis? Acta Biomed Ateneo Parmense 1995;66:125-138.
10. Rodan GA, Martin TJ. Therapeutic approaches to bone diseases. Science 2000;289:1508-1514.
11. Burg MA, Fraser K, Gui S et al. Treatment of menopausal symptoms in family medicine settings following the Women's Health Initiative Findings. J Am Board Fam Med 2006;19:122-131.
12. Regan MM, Emond SK, Attardo MJ, Parker RA, Greenspan SL. Why do older women discontinue hormone replacement therapy? J Womens Health Gend Based Med 2001;10:343-350.
13. Buffo L, Rossini M, Buoncristiano A et al. Diphosphonates: an alternative to estrogen therapy in postmenopausal osteoporosis. Experience with alendronate. Minerva Ginecol 1996;48:263-272.
14. Wronski TJ, Yen C-F, Burton KW et al. Skeletal effects of calcitonin in ovariectomized rats. Endocrinology 1991;129:2246-2250.
15. Hejdova M, Palicka V, Kucera Z, Vlcek J. Effects of alendronate and calcitonin on bone mineral density in postmenopausal osteoporotic women. An observational study. Pharm World Sci 2005;27:149-153.
16. Duarte PM, de Assis DR, Casati MZ, Sallum AW, Sallum EA, Nociti FH Jr. Alendronate may protect against increased periodontitis-related bone loss in estrogen-deficient rats. J Periodontol 2004;75:1196-1202.
17. Duarte PM, Goncalves PF, Sallum AW, Sallum EA, Casati MZ, Humberto Nociti F Jr. Effect of an estrogen-deficient state and its therapy on bone loss resulting from an experimental periodontitis in rats. J Periodont Res 2004;39:107-110.
18. Klemetti E, Collin H-L, Forss H, Markkanen H, Lassila V. Mineral status of skeleton and advanced periodontal disease. J Clin Periodontol 1994;21:184-188.
19. Johnson RB, Gilbert JA, Cooper RC et al. Alveolar bone loss one year following ovariectomy in sheep. J Periodontol 1997;68:864-871.
20. Wronski TJ, Schenck PA, Cintron M, Walsh CC. Effect of body weight on osteopenia in ovariectomized rats. Calcif Tissue Int 1987;40:155-159.
21. Nociti FH Jr, Sallum AW, Sallum EA, Duarte PM. Effect of estrogen replacement and calcitonin therapies on bone around titanium implants placed in ovariectomized rats: a histometric study. Int J Oral Maxillofac Implants 2002;17:786-792.
22. Tanaka M, Ejiri S, Toyoka E, Kohno S, Ozawa H. Effects of ovariectomy on trabecular structures of rats alveolar bone. J Periodont Res 2002;37:161-165.
23. von Wowern N, Klausen B, Kollerup G. Osteoporosis: a risk factor in periodontal disease. J Periodont 1994;65:1134-1138.
24. von Wowern N. Bone mineral content of mandibles: normal reference values - rate of age-related bone loss. Calcif Tissue Int 1988;43:193-198.
25. González D, Ghiringhell G, Mautalen C. Acute antiosteoclastic effect of salmon calcitonin in osteoporotic women. Calcif Tissue Int 1986;38:71-75.
26. Weinstein RS, Parfitt AM, Marcus R, Greenwald M, Crans G, Muchmore DB. Effects of raloxifene, hormone replacement therapy, and placebo on bone turnover in postmenopausal women. Osteoporos Int 2003;14:814-822.
27. Shen Y, Li M, Wronski TJ. Skeletal effects of calcitonin treatment and withdrawal in ovariectomized rats. Calcif Tissue Int 1996;58:263-267.
28. Gruber HE, Ivey JL, Baylink DJ et al. Long-term calcitonin therapy in post-menopausal osteoporosis. Metabolism 1984;33:295-303.
29. Messer HH, Copp DH. Changes in response to calcitonin following prolonged administration to intact rats. Proc Soc Exp Biol Med 1974;146:643-647.
30. Singer FR, Aldred JP, Neer RM, Krane SM, Potts JT, Bloch KJ. An evaluation of antibodies and clinical resistance to salmon calcitonin. J Clin Invest 1972;52:2331-2338.
31. Paganini-Hill A. The benefits of estrogen replacement therapy on oral health. Arch Intern Med 1995;155:2325-2329.
32. Yaffe A, Iztkovich M, Earon Y, Alt I, Lilov R, Binderman I. Local delivery of an amino bisphosphonates prevents the resorptive phase of alveolar bone following mucoperiosteal flap surgery in rats. J Periodontol 1997;68:884-889.
33. Rodan GA. Mechanisms of action of bisphosphonates. Annu Rev Pharmacol Toxicol 1998;38:375-388.
34. La Croix AZ. Estrogen with and without progestin: benefits and risks of short-term use. Am J Med 2005;118:79-87.
35. Hansen T, Kunkel M, Weber A, James Kirkpatrick C. Osteonecrosis of the jaws in patients treated with bisphosphonates - histomorphologic analysis in comparison with infected osteoradionecrosis. J Oral Pathol Med 2006;35:155-160.
36. Pires FR, Miranda A, Cardoso ES et al. Oral avascular bone necrosis associated with chemotherapy and biphosphonate therapy. Oral Dis 2005;11:365-369.
37. Aki S, Eskiyurt N, Akarirmak U et al. Gastrointestinal side effect profile due to the use of alendronate in the treatment of osteoporosis. Yonsei Med J 2003;44:961-967.